Abstract 119P
Background
Waiting for the highest pCR is clinically relevant as this helps to choose the candidates for a watch–and–wait approach or local excision, identify the optimal operation timing, increase the chance of R0 resection, or improve disease–free survival and/or overall survival. Meanwhile, LR is a serious problem since it causes disabling symptoms, and successful salvage of pelvic recurrence is rarely possible. Therefore, this paper will investigate the impacts of dose fractionations of preoperative radiotherapy (RT) on pCR and LR for rectal cancer using three– or four–field conformal RT techniques.
Methods
The PubMed, Embase, and Web of Science databases (2000 to May 2018) were systematically searched for evidence. To evaluate the dose–response relationship, logistic response curves were fitted for pCR values, and the linear regression model was fitted for risk reduction of LR as a function of biologic effective dose (BED).
Results
Data from 8 comparative studies enrolling 14,869 patients were analyzed for pCR. Higher radiation doses were associated with increased pCR. If pCR curve was fitted using BED as a covariate, the dose required for 50% response (D50) ranged from 68·3 to 108·0 Gy. If BED was corrected with RT overall treatment time, The pCR curves of the similar treatment regimens in special patient cohorts interacted at identical D50, 50.7, 59.0, or 70.9 Gy. Regarding LR risk, 31 studies were identified and yielded 7,699 patients. Increasing RT doses was also associated with reduction in LR, and a linear dose–response effect of BED was seen on the risk reduction of LR. Each 1 Gy increase in BED would reduce LR by 1·36%, hence a hypothesis was proposed that a BED of approximately 73.5 Gy would need to achieve 100% LC.
Conclusions
Higher radiation doses were associated with increased pCR and LR reduction. In the future, by means of dose–response curves and the available pCR and LR values, we could perhaps obtain the dose gap to achieve 50% pCR response and 100% LC, and predict the amplitude of clinical benefits through limited RT dose escalation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
74TiP - Phase I study of BI 836880, a VEGF/Ang2-blocking nanobody®, as monotherapy and in combination with BI 754091, an anti-PD-1 antibody, in Japanese patients (pts) with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract
75P - A parallel deep learning network framework for whole-body bone scan image analysis
Presenter: Xiaorong Pu
Session: Poster display session
Resources:
Abstract
76P - Perception and satisfaction of cancer patients in clinical trials
Presenter: Jukyung Jeon
Session: Poster display session
Resources:
Abstract
77P - A prognostic nomogram for the prediction of neuroblastoma
Presenter: Jian-Guo Zhou
Session: Poster display session
Resources:
Abstract
80P - The clinical usefulness of a new fat-dissociation method to detect lymph nodes from surgically resected specimen in colorectal cancer: Prospective randomized study
Presenter: Shiki Fujino
Session: Poster display session
Resources:
Abstract
81P - Concurrent or consolidation chemotherapy during radiation as neoadjuvant treatment for locally advanced rectal cancer: A propensity score analysis from two prospective study
Presenter: JianWei Zhang
Session: Poster display session
Resources:
Abstract
82P - Body mass index, tumour location, and colorectal cancer survival
Presenter: Dake Chu
Session: Poster display session
Resources:
Abstract
83P - Helicobacter bilis may play a role in the carcinogenesis of colitis associated colon cancer correlating to increased number of CD4+CD45RB+ T cells
Presenter: Xiangsheng Fu
Session: Poster display session
Resources:
Abstract
84P - Comprehensive evaluation of relapse risk (CERR) score for colorectal liver metastases development and validation
Presenter: Jianmin Xu
Session: Poster display session
Resources:
Abstract
85P - Which is the best partner for capecitabine-based neoadjuvant chemoradiotherapy in locally advanced rectal cancer? A retrospective analysis of a comprehensive cancer center
Presenter: Jingwen Wang
Session: Poster display session
Resources:
Abstract